FDA Clears New 7T MRI System from Siemens Healthineers
Offering improved image clarity capable of capturing details of subtle pathology, the Magnetom Terra.X 7T MRI system reportedly features the first eight-channel parallel transmit architecture for clinical use.
The Magnetom Terra.X., a new 7T magnetic resonance imaging (MRI) system, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
A second-generation successor to the Magnetom Terra, the Magnetom Terra.X system has a number of attributes to provide enhanced 7T imaging, according to Siemens Healthineers, the manufacturer of Magnetom Terra.X.
The Magnetom Terra.X system, recently cleared by the FDA, has a number of features including the first eight-channel parallel transmit architecture for clinical use, according to Siemens Healthineers, the manufacturer of the 7T MRI system. (Image courtesy of Siemens Healthineers.)
The company said key features of the device include:
• the first eight-channel parallel transmit architecture for clinical use;
• deep learning image reconstruction specifically geared to 7T;
• improved diffusion imaging via a high-performance gradient system; and
• accelerated image acquisition capabilities that can facilitate high-resolution brain and knee exams in less than 20 minutes.
“The MAGNETOM Terra.X builds on our engineering achievements as pioneers in 7T MRI by providing the ultra-high-field community with the necessary tools to offer higher-quality patient care not just in neurological imaging, but also in the knee,” said Katie Grant, vice president of magnetic resonance at Siemens Healthineers North America.
Siemens Healthineers added that the FDA clearance includes upgrades of installed Magnetom Terra systems to the Magnetom Terra.X.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
